HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale

* HOOKIPA Pharma (NASDAQ:HOOK [https://seekingalpha.com/symbol/HOOK]) announced voluntary delisting from the Nasdaq Capital Market.
* The company also intends to deregister its common stock and suspend SEC reporting obligations.
* Delisting follows an asset sale agreement with Gilead Sciences (GILD [https://seekingalpha.com/symbol/GILD]), transferring key assets from HB-400 (hepatitis B) and parts of HB-500 (HIV) programs.
* A special stockholder meeting is scheduled for July 29, 2025, to vote on the asset sale and proposed company dissolution. Upon approval, HOOKIPA will file for dissolution in Delaware and begin liquidation proceedings.
* Form 25 for delisting expected to be filed July 29, becoming effective around August 8, 2025.
* The decision is aimed at reducing costs and maximizing distributions to shareholders during the wind-down.
* Source: Press release [https://seekingalpha.com/pr/20171121-hookipa-pharma-announces-intention-to-voluntarily-delist-and-deregister-its-common-stock]

MORE ON HOOKIPA PHARMA

* Gilead to buy certain Hookipa Pharma assets for up to $10M [https://seekingalpha.com/news/4451640-hookipa-stock-gains-gilead-eyes-assets]
* Financial information for HOOKIPA Pharma [https://seekingalpha.com/symbol/HOOK/income-statement]